Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma:: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Lorenzo Falchi; Anna Sureda Balari; Sirpa Leppa; Joost S. P. Vermaat; Marcel Nijland; Jacob Haaber Christensen; Sven de Vos; Harald Holte; Reid W. Merryman; Pieternella Lugtenburg; Pau Abrisqueta Costa; Kim Linton; Gauri Sunkersett; Christopher Morehouse; Andrew J. Steele; Jennifer Marek; Liwei Wang; Daniela Hoehn; Martin Hutchings; David Belada

doi:10.1182/blood-2024-200262

Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Lorenzo Falchi
, Anna Sureda Balari
, Sirpa Leppa
, Joost S. P. Vermaat
, Marcel Nijland
, Jacob Haaber Christensen
, Sven de Vos
, Harald Holte
, Reid W. Merryman
, Pieternella Lugtenburg
, Pau Abrisqueta Costa
, Kim Linton
, Gauri Sunkersett
, Christopher Morehouse
, Andrew J. Steele
, Jennifer Marek
, Liwei Wang
, Daniela Hoehn
, Martin Hutchings
, David Belada

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

59 Downloads (Pure)

Original language	English
Pages (from-to)	343-344
Number of pages	2
Journal	Blood
Volume	144
DOIs	https://doi.org/10.1182/blood-2024-200262
Publication status	Published - 5 Nov 2024
Event	66th ASH Annual Meeting & Exposition - San Diego, United States Duration: 7 Dec 2024 → 10 Dec 2024 https://www.hematology.org/meetings/annual-meeting/schedule-and-program

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1182/blood-2024-200262

blood-3089-mainFinal published version, 492 KBLicence: CC BY

Cite this

Falchi, L., Balari, A. S., Leppa, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P., Costa, P. A., Linton, K., Sunkersett, G., Morehouse, C., Steele, A. J., Marek, J., Wang, L., Hoehn, D., Hutchings, M., & Belada, D. (2024). Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial. Blood, 144, 343-344. https://doi.org/10.1182/blood-2024-200262

@article{65481050a6254e7584396981cea68b30,

title = "Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma:: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial",

author = "Lorenzo Falchi and Balari, \{Anna Sureda\} and Sirpa Leppa and Vermaat, \{Joost S. P.\} and Marcel Nijland and Christensen, \{Jacob Haaber\} and \{de Vos\}, Sven and Harald Holte and Merryman, \{Reid W.\} and Pieternella Lugtenburg and Costa, \{Pau Abrisqueta\} and Kim Linton and Gauri Sunkersett and Christopher Morehouse and Steele, \{Andrew J.\} and Jennifer Marek and Liwei Wang and Daniela Hoehn and Martin Hutchings and David Belada",

year = "2024",

month = nov,

day = "5",

doi = "10.1182/blood-2024-200262",

language = "English",

volume = "144",

pages = "343--344",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

note = "66th ASH Annual Meeting \& Exposition ; Conference date: 07-12-2024 Through 10-12-2024",

url = "https://www.hematology.org/meetings/annual-meeting/schedule-and-program",

}

Falchi, L, Balari, AS, Leppa, S, Vermaat, JSP, Nijland, M, Christensen, JH, de Vos, S, Holte, H, Merryman, RW, Lugtenburg, P, Costa, PA, Linton, K, Sunkersett, G, Morehouse, C, Steele, AJ, Marek, J, Wang, L, Hoehn, D, Hutchings, M & Belada, D 2024, 'Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial', Blood, vol. 144, pp. 343-344. https://doi.org/10.1182/blood-2024-200262

TY - JOUR

T1 - Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma:

T2 - 66th ASH Annual Meeting & Exposition

AU - Falchi, Lorenzo

AU - Balari, Anna Sureda

AU - Leppa, Sirpa

AU - Vermaat, Joost S. P.

AU - Nijland, Marcel

AU - Christensen, Jacob Haaber

AU - de Vos, Sven

AU - Holte, Harald

AU - Merryman, Reid W.

AU - Lugtenburg, Pieternella

AU - Costa, Pau Abrisqueta

AU - Linton, Kim

AU - Sunkersett, Gauri

AU - Morehouse, Christopher

AU - Steele, Andrew J.

AU - Marek, Jennifer

AU - Wang, Liwei

AU - Hoehn, Daniela

AU - Hutchings, Martin

AU - Belada, David

PY - 2024/11/5

Y1 - 2024/11/5

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001412768200042&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1182/blood-2024-200262

DO - 10.1182/blood-2024-200262

M3 - Meeting Abstract

SN - 0006-4971

VL - 144

SP - 343

EP - 344

JO - Blood

JF - Blood

Y2 - 7 December 2024 through 10 December 2024

ER -

Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

UN SDGs

Access to Document

Other files and links

Cite this